Friday, July 10, 2026

Drug profile · INN

avalglucosidase alfa

avalglucosidase alfa (NEXVIADYME) is a glycogen hydrolytic enzyme.

EMA: approved PMDA: approved Alimentary tract and metabolism (A16) A16
Patents linked 0
Pipeline programs 4
News articles 1
Drug details — avalglucosidase alfa
Class
Alimentary tract and metabolism (A16)
Route
Patents
0
Programs
4
Data quality
0.83

Quick answer

avalglucosidase alfa (NEXVIADYME) is a glycogen hydrolytic enzyme.

Key facts

INN avalglucosidase alfa
Brand NEXVIADYME
Mechanism Glycogen hydrolytic enzyme
Target Glycogen
Therapeutic class Alimentary tract and metabolism (A16)
ATC code A16

Mechanism of action

Glycogen hydrolytic enzyme

Primary target: Glycogen

Approval history

Authority Status Date
EMA approved
PMDA approved

Recent coverage

Pipeline programs

  1. EFC14462 Phase 3 · Sanofi-Aventis U.S · Glycogen storage disease type II
  2. Myozyme powder for concentrate for solution f... for Pompe disease Approved · Disc Medicine · Pompe disease
  3. Nexviadyme 100 mg powder for concentrate for solution for infusion Approved · Disc Medicine · Glycogen storage disease type II or acid maltase deficiency,
  4. PTA17333 Approved · Sanofi Winthrop Industrie · Glycogen storage disease type II

Related & competitor drugs

  1. agalsidase alfa Alimentary tract and metabolism (A16)
  2. alogliptin Alimentary tract and metabolism (A10)
  3. alogliptin benzoate Alimentary tract and metabolism (A10)
  4. aprepitant Alimentary tract and metabolism (A04)
  5. budesonide Alimentary tract and metabolism (A07)
  6. canagliflozin Alimentary tract and metabolism (A10)

Frequently asked questions

What is avalglucosidase alfa?

avalglucosidase alfa (NEXVIADYME) is a glycogen hydrolytic enzyme.

What is the brand name for avalglucosidase alfa?

NEXVIADYME is a marketed brand name for avalglucosidase alfa. Check FDA Drugs@FDA for the current US label holder and prescribing information.